Liposomal delivery of triptolide fatty acid prodrugs with varied fatty acid chain lengths for breast cancer therapy
European Journal of Pharmaceutics and Biopharmaceutics · 2027-01 · 230 · 115290
DOI: 10.1016/j.ejpb.2026.115290 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2027-01. Verfasst von Yuanfa Lai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Analytical Technology and Smart Instruments, Xiamen Key Laboratory of Food and Drug Safety, College of Environment and Public Health, Xi…. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Fujian Provincial Natural Science Foundation.
Abstract (Originalsprache)
Triptolide is a highly potent natural antitumor agent whose clinical translation has been limited by systemic toxicity, narrow therapeutic window, and insufficient formulation stability. To address these limitations from a formulation-oriented perspective, a liposomal platform based on fatty acid-conjugated triptolide prodrugs was developed to investigate how fatty acid chain length influences formulation and plasma conversion behavior. Triptolide was covalently linked to myristic (C14), palmitic (C16), stearic (C18), eicosanoic (C20), and behenic (C22) acids and subsequently formulated into liposomal systems using a thin-film hydration method. The physicochemical properties were characterized, and plasma conversion, cytotoxicity, local irritation, and in vivo antitumor activity were evaluated. The free TP-FA prodrugs and their corresponding liposomal formulations exhibited distinct plasma conversion profiles. At 48 h, free TP-SA, TP-EA, and TP-BA showed conversion percentages of 97.53%, 97.02%, and 97.21%, respectively, whereas the corresponding liposomal formulations showed conversion percentages of 90.96%, 80.31%, and 41.83%, respectively. The difference between the free and liposomal forms was more persistent for the longer-chain conjugates, although the relationship with fatty acid chain length was not strictly monotonic across all time points. Among the tested formulations, behenic acid-conjugated liposomes showed distinct plasma conversion behavior and were further evaluated in the local irritation and in vivo antitumor studies. These findings suggest that saturated fatty acid chain length represents one structural variable influencing the behavior of TP-FA liposomal formulations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Analytical Technology and Smart Instruments, Xiamen Key Laboratory of Food and Drug Safety, College of Environment and Public Health, Xiamen Huaxia University, Xiamen 361024, PR China.
- Quanzhou Licheng Environmental Monitoring Station, Quanzhou 362000, PR China.
- Quanzhou Binhai Hospital, Quanzhou 362300, PR China.
- State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China.
- Institute of Analytical Technology and Smart Instruments, Xiamen Key Laboratory of Food and Drug Safety, College of Environment and Public Health, Xiamen Huaxia University, Xiamen 361024, PR China. Electronic address: z…
Förderung
- Fujian Provincial Natural Science Foundation
Zitieren
APA
Lai, Y., Huang, Z., Zhang, Q., Wu, Q., Chen, E., Guo, Z., Wang, X., & Zhang, Y. (2027). Liposomal delivery of triptolide fatty acid prodrugs with varied fatty acid chain lengths for breast cancer therapy. European Journal of Pharmaceutics and Biopharmaceutics, 230, 115290. https://doi.org/10.1016/j.ejpb.2026.115290
Vancouver
Lai Y, Huang Z, Zhang Q, Wu Q, Chen E, Guo Z, et al. Liposomal delivery of triptolide fatty acid prodrugs with varied fatty acid chain lengths for breast cancer therapy. European Journal of Pharmaceutics and Biopharmaceutics. 2027;230:115290. doi:10.1016/j.ejpb.2026.115290
BibTeX
@article{Lai2027,
author = {Lai, Yuanfa and Huang, Zhiyong and Zhang, Qihui and Wu, Qingfeng and Chen, Enxu and Guo, Zhiyong and Wang, Xiaoyi and Zhang, Yanyu},
title = {Liposomal delivery of triptolide fatty acid prodrugs with varied fatty acid chain lengths for breast cancer therapy},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2027},
volume = {230},
pages = {115290},
doi = {10.1016/j.ejpb.2026.115290}
}
EUVIMED